Table 1. Demographics of the study population in GWAS stage (stage I) for DPP-4 inhibitor pharmacogenomics study.
| Total (N = 171) | Men (N = 80) | Women (N = 91) | P (♂vs♀) | |
|---|---|---|---|---|
| Age (years) | ||||
| ≦60 years (median) | 89 (52.0%) | 43 (53.8%) | 46 (50.5%) | |
| >60 years | 82 (48.0%) | 37 (46.3%) | 45 (49.5%) | 0.679 |
| BMI (kg/m2) | ||||
| <24 | 49 (28.7%) | 23 (34.8%) | 26 (33.3%) | |
| 24-27 | 41 (24.0%) | 20 (30.3%) | 21 (26.9%) | |
| >27 | 54 (31.6%) | 23 (34.8%) | 31 (39.7%) | 0.820 |
| Missing | 27 (15.8%) | |||
| eGFR | ||||
| ≧60 (median) | 116 (67.8%) | 50 (75.8%) | 66 (89.2%) | |
| <60 | 24 (14.0%) | 16 (24.2%) | 8 (10.8%) | 0.035 |
| Missing | 31 (18.1%) | |||
| Baseline HbA1c (%) | ||||
| 7-<8% | 68 (39.8%) | 35 (43.8%) | 33 (36.3%) | |
| 8-<9% | 55 (32.2%) | 25 (31.3%) | 30 (33.0%) | |
| ≧9% | 48 (28.1%) | 20 (25.0%) | 28 (30.8%) | 0.564 |
| Changed HbA1c (%) | −0.95 ± 1.07 | −0.98 ± 1.32 | −0.92 ± 0.80 | 0.716 |
| DM duration (years) | 9.8 ± 6.5 | 9.32 ± 5.77 | 10.23 ± 7.07 | 0.361 |
| FPG (mg/dL) | 176.77 ± 47.53 | 171.38 ± 47.27 | 181.43 ± 47.53 | 0.172 |
| BP (mmHg) | ||||
| Systolic BP | 133.69 ± 15.61 | 135.32 ± 16.48 | 132.18 ± 14.79 | 0.213 |
| Diastolic BP | 80.34 ± 8.97 | 80.73 ± 9.01 | 79.97 ± 8.98 | 0.604 |
| OHA | ||||
| 1 OHA | 2 (1.2%) | 2 (2.5%) | 0 (0%) | |
| 2 OHA | 51 (29.8%) | 26 (32.5%) | 25 (27.5%) | |
| 3 OHA | 110 (64.3%) | 49 (61.3%) | 61 (67.0%) | |
| 4 OHA | 8 (4.7%) | 3 (3.8%) | 5 (5.5%) | 0.446 |
Values are presented as N (%) or mean ± SD; Abbreviation: BMI: body mass index; eGFR: estimated glomerular filtration rate; HbA1c: hemoglobin A1c; DMD: diabetes mellitus duration; FPG: fasting plasma glucose; BP: blood pressure; OHA: oral hypoglycemic agents. P value for two sample independent t test or ANOVA test